Indication
Pineoblastoma
6 clinical trials
7 products
6 drugs
Clinical trial
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH MedulloblastomaStatus: Completed, Estimated PCD: 2022-09-30
Drug
GemcitabineClinical trial
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2026-05-01
Product
SCRI-CARB7H3Drug
ribociclibProduct
sonidegibDrug
trametinibDrug
FilgrastimClinical trial
Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-26
Clinical trial
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent TumorsStatus: Active (not recruiting), Estimated PCD: 2013-01-19
Product
melphalanClinical trial
Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid TumorsStatus: Completed, Estimated PCD: 2020-12-31
Drug
AdavosertibProduct
IrinotecanDrug
busulfanProduct
Topotecan